Abstract
The treatment landscape of advanced renal cell carcinoma (RCC) is rapidly evolving. Immune checkpoint inhibitors (ICI) have now become the preferred first line treatment with the approval of nivolumab and ipilimumab combination in intermediate to poor risk patients. Combination/s of ICI with vascular endothelial growth factor (VEGF) inhibitors will also be approved in future. The optimal treatment of patients who progress on ICI-based therapies is not well defined as of yet. In this review, we discuss the data regarding various treatment options available in this space, their limitations, and also provide our opinion regarding treatment selection.
| Originalsprache | Englisch |
|---|---|
| Zeitschrift | Kidney Cancer |
| Jahrgang | 3 |
| Ausgabenummer | 2 |
| Seiten (von - bis) | 93-102 |
| Seitenumfang | 10 |
| ISSN | 2468-4562 |
| DOIs | |
| Publikationsstatus | Veröffentlicht - 2019 |
Strategische Forschungsbereiche und Zentren
- Profilbereich: Lübeck Integrated Oncology Network (LION)
- Zentren: Universitäres Cancer Center Schleswig-Holstein (UCCSH)
DFG-Fachsystematik
- 2.22-14 Hämatologie, Onkologie
- 2.22-23 Reproduktionsmedizin, Urologie
UN SDGs
Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung
